e-learning
resources
2021
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
ICS-formoterol reliever
versus
ICS and short-acting ß
2
-agonist reliever in asthma: a systematic review and meta-analysis
Lee Hatter, Pepa Bruce, Irene Braithwaite, Mark Holliday, James Fingleton, Mark Weatherall, Richard Beasley
Source:
ERJ Open Res, 7 (1) 00701-2020; 10.1183/23120541.00701-2020
Journal Issue:
January
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Lee Hatter, Pepa Bruce, Irene Braithwaite, Mark Holliday, James Fingleton, Mark Weatherall, Richard Beasley. ICS-formoterol reliever
versus
ICS and short-acting ß
2
-agonist reliever in asthma: a systematic review and meta-analysis. ERJ Open Res, 7 (1) 00701-2020; 10.1183/23120541.00701-2020
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Description of a randomised controlled trial of inhaled corticosteroid/fast-onset LABA reliever therapy in mild asthma
Source: Eur Respir J 2016; 47: 981-984
Year: 2016
Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008
Predictors of excessive short-acting beta2-agonist use and asthma exacerbations: a retrospective analysis of a Polish prescription database.
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Year: 2020
Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: an exploratory analysis of the RELIEF study in patients using formoterol as maintenance therapy
Source: Eur Respir J 2002; 20: Suppl. 38, 44s
Year: 2002
Formoterol Turbuhaler as reliever medication in patients with acute asthma
Source: Eur Respir J 2006; 27: 735-741
Year: 2006
Episodic high reliever use with budesonide/formoterol maintenance and reliever therapy confers added protection against asthma exacerbations
Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma
Year: 2007
Triple therapy
versus
single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis
Source: Eur Respir J, 52 (6) 1801586; 10.1183/13993003.01586-2018
Year: 2018
Efficacy and safety of as-needed corticosteroid plus fast or short-acting beta-agonists monotherapy in patients with mild asthma: a meta-analysis of randomised controlled trials.
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Year: 2020
Cost-effectiveness of formoterol turbuhaler versus salbutamol as reliever therapy in asthma: results from the RELIEF worldwide randomised effectiveness study
Source: Eur Respir J 2002; 20: Suppl. 38, 43s
Year: 2002
Late Breaking Abstract - Impact of maintenance and reliever therapy (MART)-focused asthma guideline on SABA prescriptions
Source: Virtual Congress 2021 – Highlights for primary care in 2021
Year: 2021
Switching asthma patients using high-dose inhaled steroids to budesonide/formoterol maintenance and reliever therapy
Source: Annual Congress 2010 - Management of airway disease
Year: 2010
Role of tiotropium in reducing exacerbations in COPD patients when added to long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS): The OUTPUL study
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013
Low dose inhaled corticosteroids (ICS) and short-acting beta-agonists (SABA) or long-acting beta-agonists (LABA) need in children and adolescents with asthma steps 1 and 2: what is the evidence?
Source: Virtual Congress 2020 – Which paediatric asthma guidelines are the most appropriate for children and adolescents?
Year: 2020
The inhaled corticosteroid/long-acting ß-agonist maintenance and reliever therapy regimen: where to from here?
Source: Eur Respir J, 51 (1) 1702338; 10.1183/13993003.02338-2017
Year: 2018
First choice in persistent asthma: inhaled corticosteroids (ICS) or ICS + long-acting beta2-agonist (LABA) combination in steroid-naïve patients?
Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids
Year: 2004
Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler
Source: ERJ Open Res 2016: 00106-2015
Year: 2016
Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination vs. high doses of ICS: efficacy and safety in patients (pts) with uncontrolled occupational asthma
Source: International Congress 2017 – Techniques to treat asthma
Year: 2017
Safety of formoterol turbuhaler when used as a reliever therapy in asthma (the RELIEF study)
Source: Eur Respir J 2002; 20: Suppl. 38, 44s
Year: 2002
Short-acting bronchodilator and oral steroid use in asthma patients prescribed either concurrent beclometasone and salmeterol or combined salmeterol/fluticasone
Source: Eur Respir J 2004; 24: Suppl. 48, 309s
Year: 2004
Safety of formoterol turbuhaler used as reliever in asthma: relationship with age and baseline treatment including regular long-acting β
2
-agonists (the RELIEF study)
Source: Eur Respir J 2002; 20: Suppl. 38, 44s
Year: 2002
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept